RecruitingPhase 1Biological interventionKK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung CancerThis is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.